Oncology Institute Inc (NASDAQ: TOI) has experienced a decline in its stock price by -7.88 compared to its previous closing price of 2.41. However, the company has seen a gain of 20.65% in its stock price over the last five trading days. Seeking Alpha reported 2023-11-10 that The Oncology Institute, Inc. (NASDAQ:TOI ) Q3 2023 Earnings Conference Call November 8, 2023 5:00 PM ET Company Participants Mark Hueppelsheuser – General Counsel Dan Virnich – Chief Executive Officer Mihir Shah – Chief Financial Officer Conference Call Participants Jack Slevin – Jefferies Operator Good afternoon, and welcome to The Oncology Institute Third Quarter 2023 earnings conference call. Today’s call is being recorded, and we have allocated one hour for prepared remarks and Q&A.
Is It Worth Investing in Oncology Institute Inc (NASDAQ: TOI) Right Now?
Additionally, the 36-month beta value for TOI is 0.96. There are mixed opinions on the stock, with 1 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The average price predicted by analysts for TOI is $2.50, which is $0.28 above the current price. The public float for TOI is 26.86M and currently, short sellers hold a 0.87% ratio of that float. The average trading volume of TOI on November 16, 2023 was 221.20K shares.
TOI’s Market Performance
TOI stock saw an increase of 20.65% in the past week, with a monthly gain of 34.55% and a quarterly increase of 163.97%. The volatility ratio for the week is 20.96%, and the volatility levels for the last 30 days are 12.79% for Oncology Institute Inc (TOI). The simple moving average for the past 20 days is 16.93% for TOI’s stock, with a 117.16% simple moving average for the past 200 days.
Analysts’ Opinion of TOI
Many brokerage firms have already submitted their reports for TOI stocks, with Guggenheim repeating the rating for TOI by listing it as a “Buy.” The predicted price for TOI in the upcoming period, according to Guggenheim is $7 based on the research report published on September 14, 2022 of the previous year 2022.
TOI Trading at 34.63% from the 50-Day Moving Average
After a stumble in the market that brought TOI to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -16.38% of loss for the given period.
Volatility was left at 12.79%, however, over the last 30 days, the volatility rate increased by 20.96%, as shares surge +37.04% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +85.00% upper at present.
During the last 5 trading sessions, TOI rose by +20.65%, which changed the moving average for the period of 200-days by +50.00% in comparison to the 20-day moving average, which settled at $1.93. In addition, Oncology Institute Inc saw 34.55% in overturn over a single year, with a tendency to cut further gains.
Reports are indicating that there were more than several insider trading activities at TOI starting from Hively Brad, who sale 47,000 shares at the price of $2.52 back on Nov 13. After this action, Hively Brad now owns 724,182 shares of Oncology Institute Inc, valued at $118,581 using the latest closing price.
BARASCH RICHARD A, the Director of Oncology Institute Inc, purchase 50,000 shares at $0.55 during a trade that took place back on Mar 17, which means that BARASCH RICHARD A is holding 257,193 shares at $27,495 based on the most recent closing price.
Stock Fundamentals for TOI
Current profitability levels for the company are sitting at:
- -28.21 for the present operating margin
- +18.89 for the gross margin
The net margin for Oncology Institute Inc stands at +0.05. The total capital return value is set at -42.40, while invested capital returns managed to touch 0.08. Equity return is now at value -59.88, with -23.82 for asset returns.
Based on Oncology Institute Inc (TOI), the company’s capital structure generated 88.05 points at debt to equity in total, while total debt to capital is 46.82. Total debt to assets is 40.13, with long-term debt to equity ratio resting at 83.51. Finally, the long-term debt to capital ratio is 44.41.
When we switch over and look at the enterprise to sales, we see a ratio of 0.69, with the company’s debt to enterprise value settled at 0.65. The receivables turnover for the company is 8.19 and the total asset turnover is 1.06. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.39.
In conclusion, Oncology Institute Inc (TOI) has seen better performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.